Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anaemia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anaemia
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Anaemia 10/28/2009 - (DGNews)
    TopAbstracts in Anaemia 10/14/2009 - (DGNews)
    TopAbstracts in Anaemia 09/30/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Anaemia
    • State of the Art in Managing Anemia in Chronic Kidney Disease
    • Current Challenges in Managing CKD-Related Anemia
    • Optimizing Hemoglobin in CKD-Related Anemia
    • A Practical Approach to Minimize the Burden of CKD-Induced Anemia
      Assuring the Safe and Appropriate Management of Anemia in Two Patient Populations: Cancer and Chronic Kidney Disease

      Webcasts/CME archive

       Recent cases - Anaemia
        A Patient with Haemolytic Anaemia Diagnosed After Thirty Years
        Severe Anemia From Bedbugs
        Orthodontic Management of Traumatic Avulsion of Permanent Incisors in a Child With Sickle Cell Anaemia: A Case Report
        Celiac Disease: It's More Common Than You Think
        A Rare Presentation of Micro-Angiopathic Haemolytic Anaemia in a Critically Ill Patient: A Case Report

        Cases archive
          




        my personal edition > anaemia > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Treat Anemia Early, Even if Mild, During Blood Cancer Therapy: Presented at ASH

        By Roberta Friedman, PhD

        SAN DIEGO, CA -- December 10, 2003 -- A randomized trial of epoetin alfa suggests that even mild anemia in cancer patients should be treated - and early - to improve their quality of life.

        The findings were reported here December 6th at the American Society of Hematology (ASH) 45th Annual Meeting.

        The number of days spent in bed or with restricted activity significantly decreased in patients treated early with epoetin. Days in bed decreased by 52.2% and 3.1% by early and late epoetin, and days with restricted activity by 41.6% and 12.2%, respectively (P = .017 for the former comparison, and for the latter, P = .042).

        Transfusion rates also decreased with earlier treatment, although missing statistical significance. Early treatment yielded 17.8% of patients needing one or more transfusion of red blood cells, compared to 26.1% of those for whom epoetin treatment was instituted later.

        Study investigator David Straus, MD, lymphoma service, Memorial Sloan-Kettering Cancer Center, New York, said, "I think this is the first randomized study to show a benefit in treating mild anemia" and added that the results might be applicable to other conditions causing anemia.

        "This is a subset of cancer patients," Dr. Straus said, "but it's provocative."

        Guidelines by ASH and American Society of Clinical Oncology suggest treating with epoetin alfa only if hemoglobin levels fall below 10 g/dL during treatment for hematologic malignancies.

        The multicenter trial tested the agent for people whose hemoglobin was not that between 10 and 12 g/dL. Half of patients were randomized to epoetin immediately if their level fell into that range, or to later treatment, holding off until their hemoglobin fell below 9 g/dL.

        Patients whose hemoglobin level was above 12 g/dL were not randomized until the level decreased to below 12 g/dL.

        The 5-year study at 14 sites included 424 enrolled patients, with 153 randomized to early and 134 to late treatment with epoetin.

        Cancers responsible for treatment in the trial of epoetin included, lymphomas and leukemias, as well as multiple myeloma.

        Ortho funded the study.


        [Study title: Early Treatment with Epoetin Alfa Improves Anemia, Quality of Life (QOL), and Productivity in Patients (Pts) with Hematologic Malignancies and Mild Anemia during Chemotherapy (CT). Abstract 1811]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send